Video
Novel OAB treatment vibegron does not adversely affect blood pressure
Author(s):
Video Player is loading.
In this video, Michael A. Weber, MD, discusses the background and findings of the study, “Effects of vibegron on ambulatory blood pressure in patients with overactive bladder: results from a double-blind study,” presented at the 2021 American Urological Association Annual Meeting. Weber is a professor of medicine and associate dean of research at Downstate College of Medicine, State University of New York, Brooklyn, New York.
Related Videos
Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
Optimizing onabotA for OAB: What are some common misconceptions?
Investigators characterize vibegron prescribing patterns for OAB
Expert outlines advantages of batteryless sacral neuromodulation device
Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
Smaller size, patient control advantages of neurostimulator for OAB
Batteryless neurostimulator found efficacious at 6-month follow-up
Colin Goudelocke, MD, on 6-month data for batteryless neurostimulator
A physical therapist’s advice for men with post-prostatectomy incontinence
Related Content
